Clinical trial
Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial
NCT03759782 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial
- Lead sponsor
- Ottawa Hospital Research Institute
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 10, 2019
- Completion date
- September 30, 2022
- Enrollment
- 24 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.